Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers.

Platinum resistance (defined as patients who had progression during first-line platinum chemotherapy or relapse within 6 months after treatment) was more frequently seen in APE1-positive cases (35.8%) as compared with APE1-negative patients (21.1%); however, this did not reach statistical significance ( P =0.09).

also in 111,027 other papers